Lulirx Spray contains Luliconazole 1% w/v, a topical antifungal agent belonging to the imidazole class, indicated for the treatment of superficial fungal infections of the skin. Luliconazole exhibits broad-spectrum antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This formulation is primarily used for the management of dermatophytosis, including tinea corporis, tinea cruris, and tinea pedis, as well as candidal infections of the skin. Lulirx Spray offers the advantage of ease of application and rapid absorption, providing effective local therapy with minimal systemic exposure. The recommended dosage involves applying a thin layer of the spray to the affected area once daily, typically for a duration of two to four weeks, depending on the severity and location of the infection. Patients should ensure the area is clean and dry before application and avoid contact with eyes and mucous membranes. Adverse effects are generally mild and may include local irritation, burning sensation, or erythema. Lulirx Spray is contraindicated in individuals with known hypersensitivity to Luliconazole or any component of the formulation. It is advisable to consult a healthcare professional before initiating treatment.